Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. (April 2015)

• Record Type: Journal Article
• Authors: Kothari, Nishi; Kim, Richard; Jorissen, Robert N.; Desai, Jayesh; Tie, Jeanne; Wong, Hui-Li; Farragher, Ian; Jones, Ian; Day, Fiona L.; Li, Shan; Sakthinandeswaren, Anuratha; Palmieri, Michelle; Lipton, Lara; Schell, Michael; Teer, Jamie K.; Shibata, David; Yeatman, Timothy; Sieber, Oliver M.; Gibbs, Peter; Tran, Ben
• Is Part Of: Acta oncologica. Volume 54:Number 4(2015)
• Page Start: 487
• Page End: 492
• Publication Date: 2015-04
• Subjects: Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.992
• Languages: English
• ISSNs: 0284-186X

Abstract

<abstract> <title>Abstract</title> <p> <bold>Background.</bold> Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring <italic>PIK3CA</italic> mutations. However, the number of <italic>PIK3CA</italic>-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with <italic>PIK3CA</italic>-mutated CRC.</p> <p> <bold>Patients and methods.</bold> Patients with <italic>PIK3CA</italic>-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, <italic>PIK3CA</italic> mutations were identified by targeted exome sequencing using the Illumina GAIIx Next Generation Sequencing platform. At RMH, Sanger sequencing was utilized. Multivariate survival analyses were conducted using Cox logistic regression.</p> <p> <bold>Results.</bold> From a cohort of 1487 CRC patients, 185 patients harbored a <italic>PIK3CA</italic> mutation. Median age of patients with PIK3CA-mutated tumors was 72 years (range: 34–92) and median follow up was 54 months. Forty-nine (26%) patients used aspirin regularly. Regular aspirin use was not associated with improved overall survival (multivariate HR 0.96, p = 0.86). There was a trend towards improved cancer-specific survival (multivariate HR 0.60, p = 0.14), but this was not significant.</p> <p> <bold>Conclusions.</bold> Despite examining a large number of patients, we did not confirm that regular aspirin use was associated with statistically significant improvements in survival in PIK3CA-mutated CRC patients. Prospective evaluation of this relationship is warranted.</p> </abstract>